Celltrion USA is excited to announce the U.S. debut of its denosumab biosimilars, STOBOCLO® and OSENVELT® (denosumab-bmwo), offering innovative and powerful new solutions for osteoporosis and bone health management
Browsing: U.S. drug launch
Celltrion USA is excited to announce the U.S. debut of its denosumab biosimilars, STOBOCLO® and OSENVELT® (denosumab-bmwo), offering innovative and powerful new solutions for osteoporosis and bone health management